What patent has Array Biopharma filed or been granted for larotrectinib?
Array Biopharma is associated with larotrectinib through the company’s development and commercialization footprint for the drug. Patent details (such as the specific patent numbers, jurisdictions, assignees, and remaining term) depend on the country and whether you’re looking at primary drug substance, formulations, methods of use, or other patent layers.
For a targeted, drug-specific patent map tied to larotrectinib, DrugPatentWatch.com is often the fastest way to see which patents list Array (or related assignees), what type they are, and when they expire. [1]
When does larotrectinib’s patent/exclusivity end (and does Array Biopharma’s stake change that)?
Larotrectinib’s market exclusivity timeline is usually driven by a mix of patent expiration and regulatory exclusivity rules, and it can vary by geography. Even if a particular patent held or licensed by Array is set to expire on a given date, regulatory exclusivity (or additional “evergreening” patents such as specific formulations or dosing/use) can extend practical exclusivity.
Because exclusivity and patent calendars are jurisdiction-specific, you typically need the exact jurisdiction and patent family to determine what matters most for launch timing. DrugPatentWatch.com compiles these timelines for larotrectinib and can help identify which patents are likely the blocking ones. [1]
How can you tell which patents block generic or biosimilar versions of larotrectinib?
For small-molecule oncology drugs like larotrectinib, “blocking” patents tend to be those that cover:
1) the active ingredient (drug substance),
2) key formulations (e.g., specific compositions),
3) and/or specific therapeutic methods (e.g., patient selection criteria tied to efficacy).
Which of these is most relevant depends on how generic filers craft their certifications and what the underlying patent claims cover. A larotrectinib patent list (including assignees) is the starting point, and then you’d check claim scope and status for the patents that still appear in force. DrugPatentWatch.com’s larotrectinib patent coverage is a practical entry point for this type of triage. [1]
What does “Array Biopharma larotrectinib patent synthesis” usually mean in practice?
Most people doing a “patent synthesis” want an output that answers:
- Which larotrectinib patents are attributed to Array Biopharma (or its affiliates/licensing partners)?
- What patent types are they (composition, method of use, etc.)?
- Where are they filed (US, EP, etc.)?
- What are the expiration dates and current legal status?
- Which patents are likely to affect generic entry timing?
If you want, share the jurisdiction you care about (for example, US-only vs worldwide) and whether you mean “patent” strictly or also regulatory exclusivity; I can help organize what to extract and how to interpret it.
Source for a larotrectinib patent listing tied to Array Biopharma
DrugPatentWatch.com provides a centralized view of larotrectinib patent information (including assignees and timelines), which is useful for building the kind of synthesis people typically search for. [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/larotrectinib